Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy
Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy
复制标题
DOI：
10.2147/ijn.s131786
复制
发表时间：
2017-01-01
影响因子：
8
通讯作者：
Pastorin, Giorgia
中科院分区：
文献类型：
--
作者：
Goh, Wei Jiang;Lee, Choon Keong;Pastorin, Giorgia
细胞衍生纳米胶囊(CDN)是一类新兴的生物药物递送系统(DDS)，它保留了来源细胞的特性，不需要进一步的表面功能化。CDN也是生物相容的，来自自然来源，还利用了由于其纳米尺寸而增强的渗透性和保留效果。此外，单核细胞来源的CDN被证明具有体内靶向效应，在先前在小鼠肿瘤模型中进行的研究中，CDN聚集在肿瘤部位。在这里，我们报告了一种与化疗药物阿霉素不同的负载方法有关的系统方法，并检测了癌细胞(HeLa)和健康细胞(HEK293)对载药CDN的不同细胞摄取。最后，我们证明了在HeLa和HEK293共培养细胞中加入阿霉素负载的CDN，在细胞水平上对癌细胞有明显的识别作用。我们的结果进一步增强了CDNS作为抗癌治疗的替代靶向策略的耐人寻味的潜力。
Cell-derived nanovesicles (CDNs) are an emerging class of biological drug delivery systems (DDS) that retain the characteristics of the cells they were derived from, without the need for further surface functionalization. CDNs are also biocompatible, being derived from natural sources and also take advantage of the enhanced permeability and retention effect due to their nanodimensions. Furthermore, CDNs derived from monocytes were shown to have an in vivo targeting effect, accumulating at the tumor site in a previous study conducted in a mouse tumor model. Here, we report a systematic approach pertaining to various loading methods of the chemotherapeutic drug doxorubicin into our CDNs and examine the differential cellular uptake of drug-loaded CDNs in cancerous (HeLa) and healthy (HEK293) cell lines. Lastly, we proved that the addition of doxorubicin-loaded CDNs to the HeLa and HEK293 co-cultures showed a clear discrimination toward cancer cells at the cellular level. Our results further reinforce the intriguing potential of CDNs as an alternative targeted strategy for anticancer therapy.